Search the Newsreel

Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip

PAVmed Inc. (PAVM) reported a narrower GAAP net loss of $5.5 million, or $0.87 per share, in Q2 2026, down from $12.3 million a year earlier, driven by lower non-cash charges. Despite progress in its Lucid Diagnostics, Veris, PortIO, and Octeris programs, the stock …

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

PAVmed Inc. reported significant progress across its businesses, including Veris Health accelerating commercial engagement with OSU-The James and advancing its implantable physiological monitor towards FDA submission. Lucid Diagnostics secured its first laboratory benefit manager coverage policy for EsoGuard and recognized $1.5 million in revenue …

PAVmed Inc. (PAVM) investor discloses 8.8% stake and trust holdings

David S. Nagelberg and the David S. Nagelberg 2003 Revocable Trust have updated their ownership report for PAVmed Inc. As of August 13, 2026, Mr. Nagelberg beneficially owns a total of 699,778 shares, representing an 8.8% stake in the company. The Trust itself holds …

PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses

PAVmed (PAVM) reported disappointing Q2 2026 earnings, missing analyst revenue estimates with $33,000 against a projected $48,960. The company continued to experience significant losses, including a -$7.0 million operating loss and -$5.4 million net loss, indicating ongoing financial challenges despite some per-share improvement year-over-year. …

PAVM Q2'26 Earnings: revenue estimate is 48.00K USD

PAVmed Inc. (PAVM) is scheduled to release its Q2'26 earnings on August 14th, with an expected revenue estimate of $48.00 thousand USD and an anticipated EPS of ($0.47). The article also provides a table comparing reported and estimated revenues and EPS from Q2'25 through …

PAVmed Inc (PAVM) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PAVmed Inc (PAVM), indicating a current earnings forecast score of 8.00 and an average price target of $12.00. Based on two analyst ratings, the stock is predominantly seen as a "Buy." The report also includes expected revenue …

PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard test

PAVmed subsidiary Lucid Diagnostics has secured a positive commercial coverage policy from Concert for its EsoGuard esophageal DNA test, effective July 2026. This policy deems EsoGuard medically necessary for patients meeting specific screening criteria for esophageal precancer and cancer, with Concert noting it as …

PAVmed to host business update call, report Q2 2026 results

PAVmed will host a business update conference call on August 14, 2026, at 8:30 a.m. ET to discuss its second-quarter 2026 results and future growth strategy. CEO Lishan Aklog and CFO Dennis McGrath will lead the call, which will be accessible via webcast on …

PAVmed Inc (PAVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of PAVmed Inc (PAVM), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock's price momentum score is 5.28, and it is trading between resistance at $6.34 and support at …

PAVMED Q1 2026 Earnings: EPS Shock Sinks Shares as Revenue Remains Unreported - Earnings Surprise Stocks

PAVM|PAVmed Inc|Price:5.285|Chg%:+0.085

This article provides a comprehensive stock analysis of PAVmed Inc (PAVM), highlighting its healthy fundamentals, high growth potential, and "fairly valued" status. It notes strong institutional ownership and a medium-term expectation for the stock price to trend down despite strong fundamentals. The analysis also …

PAVmed Inc (PAVM) Cash Flow

This article provides a detailed cash flow statement for PAVmed Inc (PAVM), including operating, investing, and financing cash flows, presented quarterly and annually. It outlines key financial metrics, such as net income from continuing operations, capital expenditures, and free cash flow. The report also …

PAVmed Inc (PAVM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for PAVmed Inc (PAVM). It indicates that PAVmed Inc has not distributed dividends in the past five years. The company has undergone several stock splits, all categorized as mergers, including a 30-to-1 split in December …

PAVmed Inc (PAVM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of PAVmed Inc (PAVM), including its major individual and institutional shareholders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with specific names and their proportional holdings. The article also mentions …

PAVmed Inc (PAVM) Balance Sheet

This article provides the quarterly and annual balance sheets for PAVmed Inc (PAVM), offering detailed financial figures for cash, assets, liabilities, and shareholder equity spanning several years. It includes frequently asked questions about balance sheet metrics, the difference between assets, liabilities, and shareholder equity, …

PAVmed Inc. Revenue Breakdown – NASDAQ:PAVM

PAVmed Inc. (NASDAQ: PAVM) reported a revenue breakdown for the last fiscal year, generating $71.00K USD, primarily from its Medical Device, Diagnostics, and Digital Health segment. This marks a significant decrease from the previous year's $3.00M USD. The United States was the largest contributor …

PAVmed Inc (PAVM) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of PAVmed Inc (PAVM), stating its current valuation score is 9.23, ranking 31st in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -0.02, noting significant deviations from its recent high and low …

PAVmed Q1 2026 Earnings: Hefty EPS Miss Masks Optimism as Stock Climbs - Low Growth Earnings

PAVM Forecast — Price Target — Prediction for 2027

PAVmed Shareholders Approve Plan Changes at Annual Meeting

PAVmed Earnings Call: Restructuring Done, Execution Ahead

PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

PAVmed (PAVM) Q1 2026 Earnings Transcript

Civmec (ASX:CVL) Margin Slippage In H1 2026 Tests Bullish Growth Narratives

Viromed Medical Aktie • A40ZVN • DE000A40ZVN7

Civmec (ASX:CVL) Earnings Under Lens — Learn What Matters

Investors Aren't Entirely Convinced By Civmec Limited's (ASX:CVL) Earnings

Civmec reports lower earnings of A$42.5 mil for full year 2025 from reduced activity levels

PAVmed CEO to Reveal Growth Strategy and Q4 Results in Upcoming Investor Call

PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q2 2024

Civmec Limited (ASX:CVL)

PAVmed Inc. (PAVM) Latest Stock News & Headlines